Cerus (CERS)

Executive Summary

Cerus Corporation is a commercial-stage biopharmaceutical company solely focused on blood safety through its proprietary INTERCEPT Blood System, which reduces pathogens in platelets, plasma, and cryoprecipitate. The company also has a late-stage red blood cell (RBC) pathogen reduction system in development. With a market cap of ~$600M and multiple approved products, Cerus generates revenue from its platelet and plasma systems, primarily in the U.S. and Europe. The RBC system, targeting a large unmet need for safer transfusions, is the key value driver, with pivotal Phase 3 data (NCT01740531) already completed for thalassemia major. The company is now preparing for regulatory submissions, including a potential Biologics License Application (BLA) to the FDA in 2026. Near-term growth catalysts include expanding international adoption of existing products, particularly in Japan and emerging markets, and progress toward RBC system approval. Risks include competition from other pathogen reduction technologies and potential delays in regulatory timelines.

Upcoming Catalysts (preview)

• Q2 2027FDA approval decision for INTERCEPT Blood System for Red Blood Cells (BLA submission)60% success
• Q1 2027CE Marking or FDA clearance for INTERCEPT cryoprecipitate pathogen reduction expansion75% success
• Q4 2026New European market launches for INTERCEPT plasma and platelets (e.g., Japan, China)80% success